Pil Soo Sung1, Hye Lim Park2, Keungmo Yang1, Seawon Hwang1, Myeong Jun Song1, Jeong Won Jang1, Jong Young Choi1, Seung Kew Yoon1, Ie Ryung Yoo3, Si Hyun Bae4. 1. Division of Hepatology, Department of Internal Medicine, The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, #505 Banpo-dong, Seocho-gu, Seoul, 06591, South Korea. 2. Division of Nuclear Medicine, Department of Radiology, College of Medicine, The Catholic University of Korea, #505 Banpo-dong, Seocho-gu, Seoul, 06591, South Korea. 3. Division of Nuclear Medicine, Department of Radiology, College of Medicine, The Catholic University of Korea, #505 Banpo-dong, Seocho-gu, Seoul, 06591, South Korea. iryoo@catholic.ac.kr. 4. Division of Hepatology, Department of Internal Medicine, The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, #505 Banpo-dong, Seocho-gu, Seoul, 06591, South Korea. baesh@catholic.ac.kr.
Abstract
PURPOSE: Sorafenib, an oral multikinase inhibitor, is a recommended treatment option available for patients with Barcelona Clinic Liver Cancer (BCLC)-C stage hepatocellular carcinoma (HCC). This study aimed to evaluate the performance of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) for predicting tumour progression during sorafenib treatment. METHODS: We formed a retrospective cohort comprising patients treated with sorafenib for at least 30 days and undergoing 18F-FDG PET/CT within 1 month before treatment. For statistical analyses, the tumour-to-liver standardised uptake value (SUV) ratio (TLR) of the most hypermetabolic lesion was measured. RESULTS: Among a total of 35 patients, two obtained partial remission, and 11 showed stable disease after the first response evaluation. Patients with a TLR ≥ 2.9 (n = 17) had a median overall survival (OS) of 3.7 months after sorafenib treatment, whereas patients with a TLR < 2.9 (n = 18) had median OS of 12.2 months (P < 0.001), although the disease control rate was not significantly different between the two groups. Pretreatment TLR ≥ 2.9 (hazard ratio [HR] = 6.318, P = 0.002) and Child-Pugh class B (HR = 4.316, P = 0.044) were poor prognostic factors for OS, and a TLR ≥ 2.9 (HR = 2.911, P = 0.024) was the only poor prognostic factor for progression-free survival in a multivariate analysis. CONCLUSION: Pretreatment tumour metabolic activity assessed by 18F-FDG PET is an independent prognostic factor for survival in patients with BCLC-C stage HCC receiving sorafenib monotherapy, although it may not predict tumour response to the treatment.
PURPOSE:Sorafenib, an oral multikinase inhibitor, is a recommended treatment option available for patients with Barcelona Clinic Liver Cancer (BCLC)-C stage hepatocellular carcinoma (HCC). This study aimed to evaluate the performance of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) for predicting tumour progression during sorafenib treatment. METHODS: We formed a retrospective cohort comprising patients treated with sorafenib for at least 30 days and undergoing 18F-FDG PET/CT within 1 month before treatment. For statistical analyses, the tumour-to-liver standardised uptake value (SUV) ratio (TLR) of the most hypermetabolic lesion was measured. RESULTS: Among a total of 35 patients, two obtained partial remission, and 11 showed stable disease after the first response evaluation. Patients with a TLR ≥ 2.9 (n = 17) had a median overall survival (OS) of 3.7 months after sorafenib treatment, whereas patients with a TLR < 2.9 (n = 18) had median OS of 12.2 months (P < 0.001), although the disease control rate was not significantly different between the two groups. Pretreatment TLR ≥ 2.9 (hazard ratio [HR] = 6.318, P = 0.002) and Child-Pugh class B (HR = 4.316, P = 0.044) were poor prognostic factors for OS, and a TLR ≥ 2.9 (HR = 2.911, P = 0.024) was the only poor prognostic factor for progression-free survival in a multivariate analysis. CONCLUSION: Pretreatment tumour metabolic activity assessed by 18F-FDG PET is an independent prognostic factor for survival in patients with BCLC-C stage HCC receiving sorafenib monotherapy, although it may not predict tumour response to the treatment.
Entities:
Keywords:
18F–FDG pet; Prognosis; Sorafenib; Time to progression; Tumour response
Authors: Markus Hartenbach; Stefan Weber; Nathalie L Albert; Sabrina Hartenbach; Albert Hirtl; Mathias J Zacherl; Philipp M Paprottka; Reinhold Tiling; Peter Bartenstein; Marcus Hacker; Alexander R Haug Journal: J Nucl Med Date: 2015-09-24 Impact factor: 10.057
Authors: Myeong Jun Song; Si Hyun Bae; Sung Won Lee; Do Sun Song; Hee Yeon Kim; Ie Ryung Yoo; Joon-Il Choi; Young June Lee; Ho Jong Chun; Hae Giu Lee; Jong Young Choi; Seung Kew Yoon Journal: Eur J Nucl Med Mol Imaging Date: 2013-02-22 Impact factor: 9.236
Authors: Jae Hoon Lee; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Hyo Jung Seo; Jong Doo Lee; Hye Jin Choi Journal: Liver Int Date: 2011-05-03 Impact factor: 5.828
Authors: Jeong Won Lee; Mijin Yun; Arthur Cho; Kwang-Hyub Han; Do Young Kim; Sang Mi Lee; Jong Doo Lee Journal: Ann Nucl Med Date: 2015-02-05 Impact factor: 2.668
Authors: Do Seon Song; Myeong Jun Song; Si Hyun Bae; Woo Jin Chung; Jae Young Jang; Young Seok Kim; Sae Hwan Lee; Jun Yong Park; Hyung Joon Yim; Sung Bum Cho; Soo Young Park; Jin Mo Yang Journal: J Gastroenterol Date: 2014-07-16 Impact factor: 6.772
Authors: Do Young Kim; Hye Jin Kim; Kwang-Hyub Han; Sang Young Han; Jeong Heo; Hyun Young Woo; Soon Ho Um; Yeul Hong Kim; Young Oh Kweon; Ho Yeong Lim; Jung Hwan Yoon; Wan Sik Lee; Byung Seok Lee; Han Chu Lee; Baek-Yeol Ryoo; Seung Kew Yoon Journal: Cancer Res Treat Date: 2016-02-24 Impact factor: 4.679
Authors: Tianying Zheng; Hanyu Jiang; Yi Wei; Zixing Huang; Jie Chen; Ting Duan; Bin Song Journal: Chin J Cancer Res Date: 2018-06 Impact factor: 5.087
Authors: Marcello Mancini; Paul Summers; Francesco Faita; Maurizia R Brunetto; Francesco Callea; Andrea De Nicola; Nicole Di Lascio; Fabio Farinati; Amalia Gastaldelli; Bruno Gridelli; Peppino Mirabelli; Emanuele Neri; Piero A Salvadori; Eleni Rebelos; Claudio Tiribelli; Luca Valenti; Marco Salvatore; Ferruccio Bonino Journal: World J Hepatol Date: 2018-02-27